**EXHIBIT A**

**THE CLAIMS WHICH WILL BE PENDING UPON ENTRY OF THE PRESENT AMENDMENT U.S. PATENT APPLICATION NO. 09/500,397**

19. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease a therapeutically effective amount of plasminogen activator effective to increase the amount of angiostatin present in said animal to treat the angiogenic disease.

20. The method of Claim 19 further comprising administering a sulfhydryl donor selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.

21. The method of Claim 19 wherein an amount of plasmin is also administered to the animal.

23. The method of Claim 19 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.

24. The method of Claim 19 wherein an amount of plasminogen is also administered to the animal.

76. The method of Claim 19 wherein said animal is a human.

77. The method of Claim 19 wherein said angiogenic disease is a neoplastic disease.

78. The method of Claim 77 wherein the neoplastic disease is a malignant tumor.

79. The method of Claim 77 wherein the neoplastic disease is a benign tumor.

80. A method of treating an angiogenic disease comprising administering to an animal suffering from such a disease a therapeutically effective amount of a plasminogen activator and a sulfhydryl donor effective to increase the amount of angiostatin present in said animal to treat the angiogenic disease.

81. The method of Claim 80 wherein the sulfhydryl donor is selected from the group consisting of cysteine, N-acetyl cysteine, captopril, D-penicillamine and reduced glutathione.

82. The method of Claim 80 wherein the plasminogen activator is selected from the group consisting of urokinase, streptokinase and tissue plasminogen activator.

83. The method of Claim 80 further comprising administering plasminogen.

84. The method of Claim 80 further comprising administering plasmin.

85. The method of Claim 80 wherein said animal is a human.

86. The method of Claim 80 wherein said angiogenic disease is a neoplastic disease.

87. The method of Claim 86 wherein the neoplastic disease is a malignant tumor.

88. The method of Claim 86 wherein the neoplastic disease is a benign tumor.

89. The method of claim 19 wherein the angiogenic disease is selected from the group consisting of neoplastic diseases including tumors and tumor metastasis; benign tumors including hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyrogenic granulomas; connective tissue disorders including rheumatoid arthritis and atherosclerosis; ocular angiogenic diseases including diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, and rubeosis; cardiovascular diseases; cerebral vascular diseases; diabetes-associated diseases; and immune disorders including chronic inflammation and autoimmunity.

90. The method of claim 80 wherein the angiogenic disease is selected from the group consisting of neoplastic diseases including tumors and tumor metastasis; benign tumors including hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyrogenic granulomas; connective tissue disorders including rheumatoid arthritis and atherosclerosis; ocular angiogenic diseases including diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, and rubeosis; cardiovascular diseases; cerebral vascular diseases; diabetes-associated diseases; and immune disorders including chronic inflammation and autoimmunity